EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

Jorine Arnouts iD, Léon C van Kempen iD, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber iD, Koen De Winne, Jonas Dahnoun und 3 weitere

International Journal of Cancer · 01.01.2027 · 160 (1) · 201-215

DOI: 10.1002/ijc.70711 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Cancer, online erschienen am 21.08.2026. Verfasst von Jorine Arnouts und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Antwerp University Hospital, Edegem, Belgium. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Servier, Interuniversity Special Research Fund, Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited. This retrospective cohort study characterized the molecular landscape of BTCs in a Belgian real‐practice setting and evaluated its prognostic relevance. Patients with BTC who underwent informative molecular testing as part of routine diagnostics at Antwerp University Hospital between 2016 and 2024 were included. Demographic, clinical, and molecular data were extracted from electronic health records. Survival outcomes were analyzed using Kaplan–Meier methods and Cox proportional hazards regression. Among 224 included patients, genomic alterations were identified in 59.4% of tumors, with clear subtype‐specific patterns. IDH1 mutations (17.3%) and FGFR2 fusions (13.9%) were exclusively observed in intrahepatic cholangiocarcinoma, KRAS mutations were most prevalent in extrahepatic cholangiocarcinoma (42.9%), and ERBB2 amplification was enriched in gallbladder cancer (16.7%). Co‐occurring alterations were present in 7.8% of cases. KRAS mutation was the most frequent alteration overall (20.4%) and remained significantly associated with worse overall survival in multivariate analysis adjusted for tumor subtype and tumor stage (HR = 1.54, 95% CI: 1.03–2.31, p = 0.04). Although 32.6% of tumors harbored a potentially actionable alteration, only 31.6% of eligible patients received matched targeted therapy. These findings underscore the clinical value of routine molecular profiling in BTC and highlight its importance for identifying therapeutic opportunities in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsBiomarkers, TumorHumansFemaleRetrospective StudiesMalePrognosisMiddle AgedBelgiumAgedMutationProto-Oncogene Proteins p21(ras)Receptor, Fibroblast Growth Factor, Type 2Kaplan-Meier EstimateIsocitrate DehydrogenaseErb-b2 Receptor Tyrosine KinasesAdultAged, 80 and over

Stichwörter der Autor:innen

biliary tract cancercholangiocarcinomagallbladder cancermolecular alterationssurvival analysis

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanBiomarkers, TumorFGFR2 protein, humanReceptor, Fibroblast Growth Factor, Type 2Isocitrate DehydrogenaseIDH1 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
  • Department of Oncology, Antwerp University Hospital, Edegem, Belgium.
  • Center for Oncological Research (CORE), University of Antwerp, Wilrijk, Belgium.
  • Department of Pathology, University of Maastricht, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Department of Hepatobiliary, Transplant and Endocrine Surgery, Antwerp University Hospital, Edegem, Belgium.
  • Antwerp Surgical Training, Anatomy and Research Centre (ASTARC), University of Antwerp, Wilrijk, Belgium.

ORCID-Profile: Jorine Arnouts, Léon C van Kempen, Laure Sorber

Förderung

  • Servier
  • Interuniversity Special Research Fund
  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Arnouts, J., van Kempen, L. C., Koljenović, S., Oliveres, H., Vanclooster, P., Prenen, H., De Weerdt, C., Chhajlani, S., Roeyen, G., Sorber, L., De Winne, K., Dahnoun, J., Vanhoutte, G., Vandamme, T., & Zwaenepoel, K. (2027). Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study. International Journal of Cancer, 160(1), 201-215. https://doi.org/10.1002/ijc.70711

Vancouver

Arnouts J, van Kempen LC, Koljenović S, Oliveres H, Vanclooster P, Prenen H, et al. Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study. International Journal of Cancer. 2027;160(1):201-215. doi:10.1002/ijc.70711

BibTeX
@article{Arnouts2027,
  author = {Arnouts, Jorine and van Kempen, Léon C and Koljenović, Senada and Oliveres, Helena and Vanclooster, Pieterjan and Prenen, Hans and De Weerdt, Caro and Chhajlani, Siddharth and Roeyen, Geert and Sorber, Laure and De Winne, Koen and Dahnoun, Jonas and Vanhoutte, Greetje and Vandamme, Timon and Zwaenepoel, Karen},
  title = {Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study},
  journal = {International Journal of Cancer},
  year = {2027},
  volume = {160},
  number = {1},
  pages = {201--215},
  doi = {10.1002/ijc.70711}
}
Kostenlos starten →